NorthWest Biotherapeutics Inc (NWBO)

[ATLnsider]

Unfortunately, his family member was his wife, Mary Pazdur. She died after a 3-Year battle with ovarian cancer:

https://cancerletter.com/obituary/20151204_1/

Dr. Richard Pazdur was able to see firsthand how solid tumor cancer patients are subjected to toxic therapies that provides very little overall survival extension, while at the same time, significantly reducing cancer patients’ quality of life (QOL).

Also, Dr. Pazdur came to understand how unethical it was to continue subjecting solid tumor cancer patients to these toxic treatments, and how unfair and expensive it was to new oncology drug and biologic Sponsors.

This enlightenment came in 2015, which was the last year that patients were enrolled into the DCVax-L trial. This enlightenment came too late to shorten the DCVax-L clinical trial.

But, this enlightenment did impact the FDA’s receptiveness to the trial’s SAP which was developed and finalized in 2020. I also believe this enlightenment will positively impact the FDA’s decision to approve DCVax-L soon.

For these and other reasons, I believe the FDA’s DCVax-L approval decision will not be far behind the MHRA’s approval decision.